September 16, 2009 — Cancer therapies are increasingly being tailored to fit the genetic profile of the patient, but new research suggests that human epidermal growth-factor receptor (HER)2 gene ...

New antibody-drug conjugates (ADCs) can target breast cancers with even the tiniest amount of HER2 expression. The old binary classification of HER2-positive or -negative has evolved into categories ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Badve is a well ...

Trastuzumab deruxtecan (T-DXd) has redefined the therapeutic landscape for breast cancer since its approval in 2019. Correspondingly, the relevance of HER2 testing beyond the traditional dichotomy of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Biomarkers are measurable indicators that can be tested to reveal important details about a cancer. Information about these biomarkers can help guide the best treatment for you, predict your response ...

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer treatment continuum. With his 23-year history at Dana-Farber Cancer Institute ...

All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent ...

The HEROES trial explores de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using the Signatera test to guide treatment decisions. The trial aims to enroll 170 patients, focusing on ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...